Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Dose Busulfan Conditioning for Allo-Transplant
NCT02483325Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Sep 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan in hematologic malignancy, sponsored by Institut Paoli-Calmettes. Primary endpoint: Progression Free Survival at 2 years. Started Sep 2014; status: completed.
02
Drugs
busulfan
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02483325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483325.